Image

Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder

Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder

Non Recruiting
7-12 years
All
Phase 4

Powered by AI

Overview

Childhood ADHD and comorbid oppositional defiant disorder (ODD) and conduct disorder (CD) are considered risk factors for subsequent substance abuse, and youth with both ADHD and ODD/CD are at greatest risk.

However, the effects of treatment of ADHD with stimulant medications such as methylphenidate (MPH) and mixed amphetamine salts (MAS) on risk for substance abuse are poorly understood. The study team propose to use fMRI to study the effects of extended release mixed amphetamine salts (MAS-XR) in drug-naïve youth 7-12 years at low risk (i.e., ADHD only) and high risk (i.e., ADHD + ODD/CD) for substance abuse on the brain reward system, to better understand the potential impact of these medications on an aspect of brain functioning which is thought to underlie vulnerability to substance abuse.

Eligibility

Inclusion Criteria:

  • General: pre-pubertal (e.g. Tanner stage 1 or 2)
  • age 7-12 inclusive
  • signed consent/assent
  • parent communicates sufficiently in English
  • Has ADHD as determined by parent interview
  • ADHD-Rating Scale-5 total score (interview with parent) of 1.5 SD > age/sex norms
  • Youth with CD or severe ODD: CD or ODD + 2 symptoms of CD

Exclusion Criteria:

  • major neurological/medical illness
  • history of head injury
  • fetal exposure to alcohol/drugs;
  • diagnosis of major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depression, generalized anxiety, social phobia, Tourette's Disorder, PTSD, autism spectrum disorder) current suicidal ideation or past history of suicide attempt
  • Wechsler Abbreviated Scale of Intelligence (WASI) score <75; 7)
  • current treatment with stimulants (prior or current treatment with non-stimulants is permitted, but participants must be off medication for 2 weeks at baseline; youth who had a past, brief stimulant medication exposure of no more than about a month, and not within the past 6 months may be included .)
  • current or past alcohol/drug use (interview; urine toxicology)
  • psychological or medical condition which precludes being in the scanner (e.g., claustrophobia, morbid obesity)
  • metal in the body that cannot be removed
  • visual disturbances that may impair task performance
  • precocious puberty (e.g. Tanner stage >2).

Study details
    Attention Deficit Disorder With Hyperactivity
    Conduct Disorder
    Substance Abuse

NCT04170738

Jeffrey Newcorn

20 August 2025

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.